Interfering with disease: a progress report on siRNA-based therapeutics

RNA interference (RNAi) quietly crept into biological research in the 1990s when unexpected gene-silencing phenomena in plants and flatworms first perplexed scientists. Following the demonstration of RNAi in mammalian cells in 2001, it was quickly realized that this highly specific mechanism of sequence-specific gene silencing might be harnessed to develop a new class of drugs that interfere with disease-causing or disease-promoting genes. Here we discuss the considerations that go into developing RNAi-based therapeutics starting from in vitro lead design and identification, to in vivo pre-clinical drug delivery and testing. We conclude by reviewing the latest clinical experience with RNAi therapeutics.

[1]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  D. Predescu,et al.  siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[3]  Stephen P. Fox,et al.  Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes: In Vitro and In Vivo Studies , 2004, Journal of drug targeting.

[4]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[5]  F. Natt,et al.  siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain , 2005, Molecular Psychiatry.

[6]  Amy C Richards Grayson,et al.  Biophysical and Structural Characterization of Polyethylenimine-Mediated siRNA Delivery in Vitro , 2006, Pharmaceutical Research.

[7]  Qing Ge,et al.  Inhibition of influenza virus production in virus-infected mice by RNA interference. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Mark E. Davis,et al.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.

[9]  M. Manoharan,et al.  RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. , 2005, Methods in enzymology.

[10]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[11]  S. Jayasena,et al.  Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.

[12]  S. W. Kim,et al.  Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[14]  Qing Ge,et al.  Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Anton P. McCaffrey,et al.  In vivo activity of nuclease-resistant siRNAs. , 2004, RNA.

[16]  F. Natt,et al.  Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[18]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[19]  P. Griffiths,et al.  Fomivirsen for the treatment of cytomegalovirus retinitis. , 2002, American journal of ophthalmology.

[20]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[21]  R. Homer,et al.  Hyperoxia causes angiopoietin 2–mediated acute lung injury and necrotic cell death , 2006, Nature Medicine.

[22]  R. Agami,et al.  Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake , 2002, BMC Neuroscience.

[23]  Gregory J. Hannon,et al.  MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies , 2005, Nature Cell Biology.

[24]  Priti Kumar,et al.  A Single siRNA Suppresses Fatal Encephalitis Induced by Two Different Flaviviruses , 2006, PLoS medicine.

[25]  Patty J. Lee,et al.  Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis* , 2004, Journal of Biological Chemistry.

[26]  S. D. De Smedt,et al.  In situ analysis of single-stranded and duplex siRNA integrity in living cells. , 2006, Biochemistry.

[27]  Ann Logan,et al.  A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids , 2005, Nucleic acids research.

[28]  Terran Lane,et al.  A computational study of off-target effects of RNA interference , 2005, Nucleic acids research.

[29]  Anastasia Khvorova,et al.  Off-target effects by siRNA can induce toxic phenotype. , 2006, RNA.

[30]  D. Scherman,et al.  Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. , 2006, Arthritis and rheumatism.

[31]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[32]  T. V. van Berkel,et al.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. , 1999, The Biochemical journal.

[33]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[34]  M. A. Rubio,et al.  Selective importation of RNA into isolated mitochondria from Leishmania tarentolae. , 2000, RNA.

[35]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[36]  G. Hutvagner,et al.  A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.

[37]  W. Marshall,et al.  Different delivery methods—different expression profiles , 2005, Nature Methods.

[38]  F. Porreca,et al.  An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons , 2005, Molecular pain.

[39]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[40]  J. Lieberman,et al.  An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection , 2006, Nature.

[41]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[42]  J. Lieberman,et al.  Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.

[43]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Chung,et al.  In vivo gene silencing (with siRNA) of pulmonary expression of MIP‐2 versus KC results in divergent effects on hemorrhage‐induced, neutrophil‐mediated septic acute lung injury , 2005, Journal of leukocyte biology.

[45]  A. Aigner.  Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. , 2006, Journal of biotechnology.

[46]  P. Campochiaro,et al.  Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 , 2006, Gene Therapy.

[47]  A. Aigner,et al.  A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[48]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[49]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[50]  F. Szoka,et al.  GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. , 2004, Advanced drug delivery reviews.

[51]  Yingjie Zhang,et al.  Engineering mucosal RNA interference in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  M. Eccles,et al.  Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells , 2004, FEBS letters.

[53]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[54]  Sangdun Choi,et al.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy , 2005, Nature Biotechnology.

[55]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[56]  R. Schiffelers,et al.  Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. , 2007, International journal of pharmaceutics.

[57]  L. Greene,et al.  Highly Efficient Small Interfering RNA Delivery to Primary Mammalian Neurons Induces MicroRNA-Like Effects before mRNA Degradation , 2004, The Journal of Neuroscience.

[58]  M. Morris,et al.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. , 2003, Nucleic acids research.

[59]  T. Zatsepin,et al.  Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. , 2005, Current pharmaceutical design.

[60]  J. Bennett,et al.  Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. , 2003, Molecular vision.

[61]  J. Schelter,et al.  Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide , 2006, PLoS genetics.

[62]  T. Tuschl,et al.  On the art of identifying effective and specific siRNAs , 2006, Nature Methods.

[63]  David P. Bartel,et al.  Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes , 2005, Cell.

[64]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[65]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[66]  P. Opolon,et al.  Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.

[67]  V. Hornung,et al.  siRNA and isRNA: two edges of one sword. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  F. Szoka,et al.  Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.

[69]  K. Arimura,et al.  Suppression of Discoidin Domain Receptor 1 by RNA Interference Attenuates Lung Inflammation1 , 2006, The Journal of Immunology.

[70]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[71]  W. Cioffi,et al.  Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. , 2005, The American journal of pathology.

[72]  R. Juliano,et al.  Tat-Conjugated PAMAM Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides , 2005, Pharmaceutical Research.

[73]  P. Jahrling,et al.  Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference , 2006, The Journal of infectious diseases.

[74]  A. Aigner,et al.  RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. , 2006, Human gene therapy.

[75]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[76]  Andrew D. Ellington,et al.  Aptamer mediated siRNA delivery , 2006, Nucleic acids research.

[77]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[78]  G. Ying,et al.  INTRAVITREAL INJECTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SMALL INTERFERING RNA INHIBITS GROWTH AND LEAKAGE IN A NONHUMAN PRIMATE, LASER-INDUCED MODEL OF CHOROIDAL NEOVASCULARIZATION , 2004, Retina.

[79]  Xiaoan Ruan,et al.  siRNA-mediated off-target gene silencing triggered by a 7 nt complementation , 2005, Nucleic acids research.

[80]  B. Polisky,et al.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication , 2005, Hepatology.

[81]  Anastasia Khvorova,et al.  Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.

[82]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature reviews genetics.

[83]  Han-Oh Park,et al.  Chemical modification of siRNAs to improve serum stability without loss of efficacy. , 2006, Biochemical and biophysical research communications.

[84]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[85]  J. Pulido,et al.  RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. , 2004, Molecular vision.

[86]  Kenneth A Howard,et al.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  Serge Batalov,et al.  Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. , 2003, Molecular cell.

[88]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[89]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[90]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[91]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[92]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[93]  L. Lim,et al.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.

[94]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[95]  K. Longmuir,et al.  Effective Targeting of Liposomes to Liver and Hepatocytes In Vivo by Incorporation of a Plasmodium Amino Acid Sequence , 2006, Pharmaceutical Research.

[96]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[97]  W. Duan,et al.  Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[98]  Takahiro Ochiya,et al.  Therapeutic potential of RNA interference against cancer , 2006, Cancer science.

[99]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[100]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[101]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[102]  Vladimir P Torchilin,et al.  Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. , 2006, Annual review of biomedical engineering.

[103]  P. Tan,et al.  Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat , 2005, Gene Therapy.

[104]  R. Juliano.  Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. , 2005, Current opinion in molecular therapeutics.

[105]  Jindrich Kopecek,et al.  Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. , 2002, Advanced drug delivery reviews.

[106]  Kyung Chul Cho,et al.  Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[107]  A. Aigner,et al.  RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo , 2005, Gene Therapy.